Year: 2025
Type: article
Study design: Observational Study
Abstract: Purpose: Epstein-Barr virus(EBV)IgA serology for viral capsid antigen(VCA)and early antigen(EA)aids early detection of nasopharyngeal cancer(NPC) , resulting in improved survival.We evaluated the diagnostic performance of a prefabricated immunofluorescent assay(IFA)for NPC screening in high-risk individuals.Methods: Sera from 96 biopsy-proven patients with NPC diagnosed at the outpatient clinic and 96 healthy family members were tested for EBV-VCA IgA and EBV-EA IgA using the prefabricated IFA from EUROIMMUN(EI)and the traditional immunofluorescence method.Results and discussion: The AUC of EI EBV-VCA IgA and EBV-EA IgA was 0． 907(95％ confidence interval［CI］ : 0． 894-0． 965)and 0． 898(95％ CI: 0． 848-0． 947) , respectively.Combined testing with the prefabricated assay at a threshold of VCA ≥1: 320 or EA ≥1: 10 showed 92.7％ sensitivity and 81． 2％ specificity.Overall, the traditional EBV-EA IgA assay demonstrated the best accuracy(sensitivity 91． 7％ and specificity 96． 9％)at a threshold of ≥1: 5． Conclusion: While the traditional IFA method was more accurate, the prefabricated IFA test kit can be a useful tool for NPC screening in high-risk populations.
Authors: Chair: Tsutomu Ueda, Hideaki Takahashi
Institutions: Hiroshima University, National Cancer Center Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415289000
FWCI:
Cites:
Cited by:
Related to: